Vimarsana
Biggest News Aggregation in the World

Page 37 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022 - Vimarsana News

BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient

LVW Advisors LLC Sells 193 Shares of BeiGene, Ltd. (NASDAQ:BGNE) - Vimarsana News

LVW Advisors LLC Sells 193 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

LVW Advisors LLC lowered its stake in BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 9.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,799 shares of the company’s stock after selling 193 shares during the period. LVW Advisors LLC’s holdings in BeiGene were worth $487,000 […]

China's financial regulator plans new approach to break deadlock with the US over auditing work - Vimarsana News

China's financial regulator plans new approach to break deadlock with the US over auditing work

The plan relegates the CSRC to the back seat in the auditing dispute between the US and China, from the role it has held since 2016 as the collector and gatekeeper of China’s audit working papers.

Source: scmp.com
Fierce Pharma Asia—Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from Lilly - Vimarsana News

Fierce Pharma Asia—Eisai's reduced Aduhelm role; Chinese biotechs' US delisting risks; Zai Lab's new COO from Lilly

Eisai has decided to exit its supporting role for Biogen's Alzheimer's drug Aduhelm. Chinese companies including several biotechs face potential U.S.

BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to "Market Perform" - Vimarsana News

BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to "Market Perform"

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by research analysts at SVB Leerink from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, Briefing.com reports. They currently have a $177.00 price target on the stock, down from their previous price target of $300.00. SVB Leerink’s price target points to […]